# ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

> **NCT06498479** · PHASE3 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 460 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** HS-20093
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT06498479
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-04
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-05-31
- **Target enrollment:** 460 (ESTIMATED)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06498479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06498479, "ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06498479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*